ArticleHuman vaccines & immunotherapeutics2025
A 14-year influenza reinfection surveillance in Chongqing, China: A retrospective analysis.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preliminary Safety Assessment of a Quadrivalent Subunit Influenza Vaccine in China: A Phase IV Study.Infectious diseases and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza poses a significant medical burden and has the potential to cause global pandemics. To better understand the epidemiological characteristics of influenza reinfections and identify factors associated with an increased risk of reinfection, we analyzed influenza data from 2010 to 2023 obtained from the National Notifiable Infectious Disease Reporting Information System in Chongqing, China. The Andersen-Gill model was used to evaluate the association between demographic characteristics and the risk of reinfection. A total of 676,811.47 person-years were observed, with a median time to reinfection of 9.40 months. The log-rank test revealed significant differences in reinfection probability by sex, age, occupation, and residence (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.